Incyte said on Monday it will buy Vega ​Therapeutics, a wholly owned subsidiary of privately held Star Therapeutics, in a deal ‌worth up to $2 billion, expanding its pipeline for blood disorder therapies.

WILMINGTON, Del. --(BUSINESS WIRE)--Nov. 18, 2024-- Incyte (Nasdaq:INCY) today announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 (INCB000262) in chronic spontaneous urtic...

Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

Reported Monday, Sep 28 - 2:08pm EDT (TheFly subscription required to read more.)

US biotech Incyte Pharma is ​nearing a deal ‌for up to $2 billion to buy ​blood disorder ​drug developer Star Therapeutics, ⁠the Financial ​Times reported on Sunday, ​citing people familiar with the matter.

Reported Monday, Sep 28 - 9:24am EDT (TheFly subscription required to read more.)

Incyte’s monoclonal antibody Monjuvi reduced certain follicular lymphoma patients’ risk of progression, relapse or death by 57% compared to placebo, the company announced Monday.

Score 7/10 · Impatto: Medium · Finestra: 3 days Asset: XBI, IBB, MRM, INCY Biotech-heavy ETFs may experience localized volatility as the market reprices the commercial potential of Mirum and Incyte following this regulatory approval.

Incyte's Monjuvi as part of a multi-drug regimen that includes a chemotherapy standard of care ‌for an aggressive form of non-Hodgkin lymphoma reduced the risk of disease progression, relapse or death by 25% compared to the standard alone, but with a higher rate of study dropouts due to side effects.

YourChoice Therapeutics, working with Quotient Sciences and Incyte, reports that single oral doses of the investigational non‑hormonal male contraceptive YCT‑529 up to 180 mg produced no clinically re...

Drugmaker Incyte Corp reported on Tuesday higher second-quarter earnings and raised its annual revenue forecast after it settled ​a lawsuit with the U.S. government over Medicaid rebates ‌tied to eczema cream Opzelura.

Incyte said on Monday its experimental combo therapy helped patients with a type of blood cancer live longer without their disease worsening in a late-stage study.

These are some of the stocks posting the largest midday moves.